ABX 196
Alternative Names: ABX-196Latest Information Update: 14 May 2026
At a glance
- Originator Brigham Young University; The Scripps Research Institute; University of Chicago
- Developer Abivax
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immunostimulants; Natural killer T cell stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Liver cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Liver-cancer(In volunteers) in France (IM, Injection)
- 31 Dec 2022 Discontinued - Phase-I for Liver cancer (In volunteers) in France (IM)
- 31 Dec 2022 Discontinued - Phase-I/II for Liver cancer (Combination therapy, Inoperable/Unresectable, Second-line therapy or greater) in USA (IM)